Grant: Discovery Grants Program - Individual
University of British Columbia
$60,000.00
New marine natural product tools for drug discovery and chemical genetics
EF 2007-08
Résumé
More than half of currently used drugs are derived from 'natural products'. Marine animals and microbes represent the greatest unexplored source of new 'natural products' for drug discovery. Our proposed research is designed to discover 'marine natural products' that will provide lead compounds for developing drug candidates for new approaches to treating: a) diabetes and obesity, b) SARS, c) rejection of organ transplants, and d) cystic fibrosis. Diabetes affects 2 million Canadians and costs the country 9 billion dollars annually. Patients suffering from diabetes or obesity experience shortened life expectancy and are susceptible to hypertension, cardiovascular disease, cancer, stroke, kidney failure, and blindness. Human pancreatic alpha amylase (HPA) is a promising target for the development of new drugs for treating diabetes and obesity. We are proposing to search for new inhibitors of HPA. SARS first appeared in China and eventually spread worldwide, including to Canada. During the 2002 outbreak, 9000 individuals contracted SARS and there were 774 fatalities. There are no small molecule drugs to treat SARS. We are proposing to search for inhibitors of the SARS protease, 3CLpro, which has been identified as a promising target for developing anti-SARS drugs. Calcineurin, a protein phosphatase, is the indirect cellular target of the immunosuppressive drugs cyclosporine and FK506. Even though these are important drugs that have revolutionized organ transplantation, they have serious side effects. Despite the clinical importance of calcineurin inhibitors, there are no good active-site inhibitors of this phosphatase known. We are proposing to search for active-site inhibitors of calcineurin that would act as leads for development of a new class of immunosuppressive drugs. Cystic Fibrosis (CF) is the most common lethal genetic disease affecting Caucasians. CF patients have an expected life span of only 34 years. CF is caused by a phenylalanine deletion (deltaF508) mutation in the CFTR gene leading to misfolding and decreased function of the CFTR gene product. We propose to search for deltaF508-CFTR defect 'correctors', which are hypothesized to be useful drugs for treating CF.
Programme
Discovery Grants Program - Individual
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
869-2007
Name nom
Andersen, Raymond
Department département
Chemistry
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2007
Competition year année de concours
2007
Award amount
60000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
24
Committee name en
Inorganic & Organic Chemistry
Committee name fr
Chimie inorg. et org.
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3701
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Natural products
Research subject fr
Produits naturels
Partie
1
Nb partie
1
Application title
New marine natural product tools for drug discovery and chemical genetics
Keyword
NA
Application summary
More than half of currently used drugs are derived from 'natural products'. Marine animals and microbes represent the greatest unexplored source of new 'natural products' for drug discovery. Our proposed research is designed to discover 'marine natural products' that will provide lead compounds for developing drug candidates for new approaches to treating: a) diabetes and obesity, b) SARS, c) rejection of organ transplants, and d) cystic fibrosis. Diabetes affects 2 million Canadians and costs the country 9 billion dollars annually. Patients suffering from diabetes or obesity experience shortened life expectancy and are susceptible to hypertension, cardiovascular disease, cancer, stroke, kidney failure, and blindness. Human pancreatic alpha amylase (HPA) is a promising target for the development of new drugs for treating diabetes and obesity. We are proposing to search for new inhibitors of HPA. SARS first appeared in China and eventually spread worldwide, including to Canada. During the 2002 outbreak, 9000 individuals contracted SARS and there were 774 fatalities. There are no small molecule drugs to treat SARS. We are proposing to search for inhibitors of the SARS protease, 3CLpro, which has been identified as a promising target for developing anti-SARS drugs. Calcineurin, a protein phosphatase, is the indirect cellular target of the immunosuppressive drugs cyclosporine and FK506. Even though these are important drugs that have revolutionized organ transplantation, they have serious side effects. Despite the clinical importance of calcineurin inhibitors, there are no good active-site inhibitors of this phosphatase known. We are proposing to search for active-site inhibitors of calcineurin that would act as leads for development of a new class of immunosuppressive drugs. Cystic Fibrosis (CF) is the most common lethal genetic disease affecting Caucasians. CF patients have an expected life span of only 34 years. CF is caused by a phenylalanine deletion (deltaF508) mutation in the CFTR gene leading to misfolding and decreased function of the CFTR gene product. We propose to search for deltaF508-CFTR defect 'correctors', which are hypothesized to be useful drugs for treating CF.